CytomX Therapeutics says focus on development of CRC treatment CX-2051 in FY25

“CytomX Therapeutics (CTMX) announced updated pipeline priorities and anticipated milestones for 2025. “Our top strategic objective for 2025 is the development of CX-2051, a wholly-owned, first-in-class PROBODY ADC being developed initially in advanced metastatic colorectal cancer or CRC. CX-2051 targets the previously undruggable highly expressed CRC antigen, EpCAM, and carries a topoisomerase-1 inhibitor payload. This novel ADC has the potential to make a meaningful difference in the treatment of heavily pretreated CRC patients, for whom the current standard of care remains inadequate and new treatment options are urgently needed. We are encouraged by our early clinical progress and remain on track to deliver initial Phase 1a dose escalation data in the first half of 2025,” said Sean McCarthy, D.Phil., chief executive officer and chairman of CytomX. Dr. McCarthy continued, “As we look ahead to 2025, we are taking steps to focus our strategy and capital allocation, further concentrating efforts on wholly-owned clinical stage programs that we believe have the greatest potential for near-term value inflection. We also continue the important work we are doing with our collaboration partners, including ongoing clinical evaluation of CX-904 with Amgen. As we enter 2025, we have taken the difficult decision to streamline our organization and resources towards top priorities and we look forward to sharing progress from our pipeline throughout the year.”